A Phase 3 interventional study of V116 and PPSV23 in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 92 sites in 13 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 6th largest by enrollment, is the only one that started in 2024, is one of 9 in phase 3, and was the 8th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2024.
This study's enrollment of 882 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 15th largest by enrollment, is the only one that started in 2024, is one of 31 in phase 3, and was the 42nd registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1
Biological: V116
Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
Biological: PPSV23
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Also known as: Pneumococcal 21-valent Conjugate Vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Also known as: PNEUMOVAX™23
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling.
Time frame: Up to 5 days postvaccination
Percentage of Participants With Solicited Systemic AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included muscle aches all over the body (myalgia), headache, tiredness (fatigue), hives or welts (urticaria), irritability, joint pain (arthralgia), drowsiness (somnolence), feeling sick (malaise), and fever (pyrexia).
Time frame: Up to 5 days post vaccination
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
A vaccine-related SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event.
Time frame: Up to approximately 6 months
Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) Responses
Opsonophagocytic activity (OPA) for the serotypes in V116 will be determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: 30 days postvaccination
Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) After Vaccination
The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (PnECL). Serotype-specific IgGs and GMC ratios with 95% CIs were calculated using a cLDA model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: 30 days postvaccination
Geometric Mean Fold Rise (GMFR) From Baseline in Serotype-specific OPA GMTs
The GMFR from baseline in serotype-specific OPA GMTs was determined using MOPA at baseline and 30 days postvaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal OPA serotype was calculated. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: Baseline (Day 1) and 30 days postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs GMTs
The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMTs of each pneumococcal serotype was calculated. Titer levels were determined by the MOPA and derived from a cLDA model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: Baseline (Day 1) and Day 30 postvaccination
GMFR From Baseline in Serotype-specific IgG GMCs
The GMFR from baseline in serotype-specific IgG GMCs was determined using PnECL at baseline and 30 days postvaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific IgG GMCs
The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMCs of each pneumococcal serotype was calculated. Titer levels were determined by PnECL and derived from a cLDA model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: Baseline (Day 1) and Day 30 postvaccination
| Milestone | V116 | PPSV23 |
|---|---|---|
| Started | 531 | 351 |
| Vaccinated | 528 | 348 |
| Safety analysis population | 527 | 347 |
| Completed | 522 | 345 |
| Not completed | 9 | 6 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Randomized by mistake without study treatment | 1 | 1 |
| Withdrew: Withdrawal by parent/guardian | 5 | 3 |
| Withdrew: Randomized by mistake with study treatment | 1 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling.
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Injection site erythema | 24.3 | 16.4 |
| Injection site pain | 67.7 | 54.5 |
| Injection site swelling | 18.8 | 18.2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included muscle aches all over the body (myalgia), headache, tiredness (fatigue), hives or welts (urticaria), irritability, joint pain (arthralgia), drowsiness (somnolence), feeling sick (malaise), and fever (pyrexia).
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Arthralgia | 4.4 | 5.5 |
| Fatigue | 20.1 | 21.0 |
| Headache | 17.1 | 15.3 |
| Irritability | 11.6 | 11.0 |
| Malaise | 13.3 | 9.2 |
| Myalgia | 6.3 | 5.2 |
| Pyrexia | 4.6 | 5.8 |
| Somnolence | 9.5 | 9.2 |
| Urticaria | 2.7 | 1.7 |
A vaccine-related SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event.
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) | 0.2 | 0.6 |
Opsonophagocytic activity (OPA) for the serotypes in V116 will be determined using a multiplexed opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Titers | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 526.6 (NA to NA) | 517.0 (NA to NA) |
| Serotype 7F | 20618.1 (NA to NA) | 14207.2 (NA to NA) |
| Serotype 8 | 12294.5 (NA to NA) | 8966.9 (NA to NA) |
| Serotype 9N | 35556.8 (NA to NA) | 18587.8 (NA to NA) |
| Serotype 10A | 13719.7 (NA to NA) | 5363.8 (NA to NA) |
| Serotype 11A | 10396.3 (NA to NA) | 3129.8 (NA to NA) |
| Serotype 12F | 14752.0 (NA to NA) | 4820.1 (NA to NA) |
| Serotype 17F | 40011.8 (NA to NA) | 11267.4 (NA to NA) |
| Serotype 19A | 9009.8 (NA to NA) | 9797.6 (NA to NA) |
| Serotype 20A | 37532.2 (NA to NA) | 14787.0 (NA to NA) |
| Serotype 22F | 20162.7 (NA to NA) | 7770.3 (NA to NA) |
| Serotype 33F | 73201.8 (NA to NA) | 40609.0 (NA to NA) |
| Serotype 6A | 16910.9 (NA to NA) | 5653.8 (NA to NA) |
| Serotype 15A | 69527.8 (NA to NA) | 5332.2 (NA to NA) |
| Serotype 15C | 34539.1 (NA to NA) | 4398.4 (NA to NA) |
| Serotype 16F | 31544.9 (NA to NA) | 5449.7 (NA to NA) |
| Serotype 23A | 28591.7 (NA to NA) | 4882.0 (NA to NA) |
| Serotype 23B | 5988.2 (NA to NA) | 370.5 (NA to NA) |
| Serotype 24F | 11102.2 (NA to NA) | 2771.8 (NA to NA) |
| Serotype 31 | 46163.7 (NA to NA) | 2563.0 (NA to NA) |
| Serotype 35B | 40102.8 (NA to NA) | 7812.5 (NA to NA) |
The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (PnECL). Serotype-specific IgGs and GMC ratios with 95% CIs were calculated using a cLDA model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| μg/mL | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 1.56 (NA to NA) | 1.88 (NA to NA) |
| Serotype 7F | 7.33 (NA to NA) | 7.37 (NA to NA) |
| Serotype 8 | 13.68 (NA to NA) | 17.86 (NA to NA) |
| Serotype 9N | 7.11 (NA to NA) | 9.41 (NA to NA) |
| Serotype 10A | 8.47 (NA to NA) | 4.69 (NA to NA) |
| Serotype 11A | 7.47 (NA to NA) | 4.32 (NA to NA) |
| Serotype 12F | 1.78 (NA to NA) | 1.38 (NA to NA) |
| Serotype 17F | 14.75 (NA to NA) | 6.13 (NA to NA) |
| Serotype 19A | 13.50 (NA to NA) | 15.97 (NA to NA) |
| Serotype 20A | 9.09 (NA to NA) | 5.75 (NA to NA) |
| Serotype 22F | 14.20 (NA to NA) | 10.23 (NA to NA) |
| Serotype 33F | 6.75 (NA to NA) | 9.34 (NA to NA) |
| Serotype 6A | 11.98 (NA to NA) | 6.25 (NA to NA) |
| Serotype 15A | 12.00 (NA to NA) | 1.24 (NA to NA) |
| Serotype 15C | 13.54 (NA to NA) | 2.55 (NA to NA) |
| Serotype 16F | 2.35 (NA to NA) | 0.18 (NA to NA) |
| Serotype 23A | 7.17 (NA to NA) | 1.05 (NA to NA) |
| Serotype 23B | 6.47 (NA to NA) | 1.29 (NA to NA) |
| Serotype 24F | 2.39 (NA to NA) | 0.22 (NA to NA) |
| Serotype 31 | 4.67 (NA to NA) | 0.27 (NA to NA) |
| Serotype 35B | 8.96 (NA to NA) | 0.89 (NA to NA) |
The GMFR from baseline in serotype-specific OPA GMTs was determined using MOPA at baseline and 30 days postvaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal OPA serotype was calculated. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Ratio | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 7.9 (6.8 to 9.1) | 7.6 (6.4 to 9.0) |
| Serotype 7F | 15.8 (13.7 to 18.3) | 10.5 (9.0 to 12.4) |
| Serotype 8 | 30.5 (25.9 to 36.0) | 21.7 (17.8 to 26.4) |
| Serotype 9N | 13.9 (12.1 to 15.9) | 8.0 (6.8 to 9.3) |
| Serotype 10A | 15.4 (12.5 to 19.0) | 6.0 (4.7 to 7.5) |
| Serotype 11A | 18.6 (14.9 to 23.4) | 5.9 (4.5 to 7.8) |
| Serotype 12F | 452.7 (378.6 to 541.4) | 149.3 (122.1 to 182.6) |
| Serotype 17F | 33.3 (28.3 to 39.2) | 9.9 (8.2 to 11.8) |
| Serotype 19A | 6.6 (5.6 to 7.7) | 7.2 (6.1 to 8.7) |
| Serotype 20A | 10.4 (9.0 to 12.0) | 4.1 (3.5 to 4.9) |
| Serotype 22F | 22.2 (18.3 to 26.8) | 8.4 (6.8 to 10.3) |
| Serotype 33F | 18.2 (16.1 to 20.5) | 10.0 (8.6 to 11.6) |
| Serotype 6A | 22.1 (17.8 to 27.4) | 7.1 (5.6 to 9.0) |
| Serotype 15A | 26.6 (23.3 to 30.4) | 2.0 (1.8 to 2.3) |
| Serotype 15C | 124.5 (95.0 to 163.3) | 13.4 (10.2 to 17.7) |
| Serotype 16F | 7.6 (6.7 to 8.6) | 1.5 (1.3 to 1.6) |
| Serotype 23A | 14.2 (11.7 to 17.2) | 2.2 (1.8 to 2.7) |
| Serotype 23B | 92.9 (70.3 to 122.8) | 6.2 (4.5 to 8.4) |
| Serotype 24F | 4.4 (3.8 to 5.1) | 1.1 (0.9 to 1.3) |
| Serotype 31 | 28.8 (24.1 to 34.4) | 1.6 (1.3 to 1.8) |
| Serotype 35B | 6.0 (5.3 to 6.8) | 1.3 (1.2 to 1.4) |
The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMTs of each pneumococcal serotype was calculated. Titer levels were determined by the MOPA and derived from a cLDA model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 64.6 (59.8 to 69.3) | 66.1 (60.1 to 71.6) |
| Serotype 7F | 84.2 (80.3 to 87.5) | 79.7 (74.4 to 84.3) |
| Serotype 8 | 92.3 (89.2 to 94.8) | 90.6 (86.3 to 93.9) |
| Serotype 9N | 82.8 (78.8 to 86.3) | 71.7 (65.9 to 77.0) |
| Serotype 10A | 73.5 (68.7 to 77.9) | 47.5 (41.2 to 53.8) |
| Serotype 11A | 76.2 (71.7 to 80.4) | 46.2 (39.9 to 52.6) |
| Serotype 12F | 96.7 (94.5 to 98.2) | 96.0 (93.0 to 98.0) |
| Serotype 17F | 92.4 (89.3 to 94.8) | 74.0 (68.2 to 79.3) |
| Serotype 19A | 57.8 (52.9 to 62.7) | 64.0 (58.0 to 69.7) |
| Serotype 20A | 77.8 (73.2 to 82.0) | 48.0 (41.8 to 54.4) |
| Serotype 22F | 84.1 (80.1 to 87.5) | 65.3 (59.2 to 71.0) |
| Serotype 33F | 88.9 (85.5 to 91.8) | 74.2 (68.5 to 79.3) |
| Serotype 6A | 76.3 (71.7 to 80.5) | 55.7 (49.2 to 62.0) |
| Serotype 15A | 91.3 (88.0 to 93.8) | 22.8 (17.9 to 28.3) |
| Serotype 15C | 90.7 (87.2 to 93.5) | 68.9 (62.6 to 74.7) |
| Serotype 16F | 67.5 (62.7 to 72.1) | 13.5 (9.6 to 18.3) |
| Serotype 23A | 75.2 (70.2 to 79.8) | 27.4 (21.6 to 33.8) |
| Serotype 23B | 78.2 (73.8 to 82.2) | 42.7 (36.4 to 49.2) |
| Serotype 24F | 47.6 (42.3 to 52.9) | 7.9 (4.7 to 12.4) |
| Serotype 31 | 89.9 (86.4 to 92.7) | 13.6 (9.6 to 18.5) |
| Serotype 35B | 60.7 (55.7 to 65.6) | 7.8 (4.8 to 11.8) |
The GMFR from baseline in serotype-specific IgG GMCs was determined using PnECL at baseline and 30 days postvaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F.
| Ratio | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 5.8 (5.0 to 6.6) | 6.6 (5.5 to 7.9) |
| Serotype 7F | 23.0 (20.4 to 26.0) | 23.3 (20.2 to 26.9) |
| Serotype 8 | 34.5 (30.4 to 39.1) | 40.5 (34.4 to 47.7) |
| Serotype 9N | 22.5 (19.5 to 26.0) | 31.5 (26.4 to 37.7) |
| Serotype 10A | 20.4 (17.9 to 23.2) | 12.3 (10.3 to 14.8) |
| Serotype 11A | 13.7 (11.7 to 16.0) | 7.5 (6.2 to 8.9) |
| Serotype 12F | 22.6 (20.1 to 25.3) | 17.5 (14.8 to 20.6) |
| Serotype 17F | 41.6 (36.6 to 47.4) | 16.7 (14.2 to 19.7) |
| Serotype 19A | 8.1 (6.9 to 9.5) | 9.3 (7.5 to 11.4) |
| Serotype 20A | 11.4 (10.1 to 12.9) | 7.1 (6.1 to 8.3) |
| Serotype 22F | 41.8 (34.7 to 50.4) | 35.7 (28.5 to 44.8) |
| Serotype 33F | 19.9 (17.7 to 22.3) | 26.3 (22.1 to 31.2) |
| Serotype 6A | 25.9 (21.7 to 31.0) | 13.1 (10.8 to 15.9) |
| Serotype 15A | 32.0 (27.8 to 36.9) | 3.3 (2.8 to 3.9) |
| Serotype 15C | 42.4 (36.8 to 48.9) | 7.4 (6.2 to 9.0) |
| Serotype 16F | 15.4 (13.6 to 17.5) | 1.4 (1.2 to 1.5) |
| Serotype 23A | 28.8 (24.8 to 33.5) | 4.1 (3.4 to 4.8) |
| Serotype 23B | 18.3 (15.3 to 21.9) | 3.4 (2.9 to 4.1) |
| Serotype 24F | 12.6 (10.8 to 14.7) | 1.1 (1.0 to 1.2) |
| Serotype 31 | 25.3 (22.4 to 28.6) | 1.5 (1.4 to 1.7) |
| Serotype 35B | 10.1 (8.8 to 11.5) | 1.0 (1.0 to 1.1) |
The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMCs of each pneumococcal serotype was calculated. Titer levels were determined by PnECL and derived from a cLDA model. The 12 common pneumococcal serotypes in both V116 and PPSV23 were as follows: 3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 9 unique pneumococcal serotypes in V116 were as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 59.3 (54.1 to 64.5) | 62.2 (55.6 to 68.5) |
| Serotype 7F | 92.5 (89.2 to 95.0) | 97.4 (94.4 to 99.0) |
| Serotype 8 | 94.4 (91.5 to 96.6) | 94.8 (91.1 to 97.3) |
| Serotype 9N | 88.0 (84.2 to 91.2) | 92.2 (87.9 to 95.3) |
| Serotype 10A | 88.0 (84.2 to 91.2) | 80.9 (75.2 to 85.7) |
| Serotype 11A | 77.2 (72.5 to 81.4) | 63.9 (57.3 to 70.1) |
| Serotype 12F | 93.3 (90.2 to 95.7) | 88.7 (83.9 to 92.5) |
| Serotype 17F | 95.5 (92.8 to 97.4) | 87.4 (82.4 to 91.4) |
| Serotype 19A | 63.8 (58.6 to 68.8) | 67.0 (60.5 to 73.0) |
| Serotype 20A | 78.8 (74.2 to 82.9) | 66.1 (59.6 to 72.2) |
| Serotype 22F | 85.5 (81.4 to 89.0) | 87.0 (81.9 to 91.0) |
| Serotype 33F | 91.1 (87.6 to 93.8) | 91.3 (86.9 to 94.6) |
| Serotype 6A | 83.8 (79.6 to 87.5) | 76.5 (70.5 to 81.8) |
| Serotype 15A | 92.8 (89.6 to 95.2) | 37.4 (31.1 to 44.0) |
| Serotype 15C | 94.2 (91.2 to 96.3) | 63.9 (57.3 to 70.1) |
| Serotype 16F | 85.8 (81.7 to 89.2) | 7.0 (4.0 to 11.1) |
| Serotype 23A | 89.4 (85.8 to 92.4) | 43.9 (37.4 to 50.6) |
| Serotype 23B | 76.0 (71.3 to 80.4) | 39.6 (33.2 to 46.2) |
| Serotype 24F | 75.2 (70.4 to 79.6) | 3.0 (1.2 to 6.2) |
| Serotype 31 | 93.3 (90.2 to 95.7) | 7.4 (4.4 to 11.6) |
| Serotype 35B | 76.6 (71.9 to 80.9) | 0.9 (0.1 to 3.1) |
Collected over Up to approximately 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V116 | 0/531 (0%) | 29/527 (5.5%) | 408/527 (77.4%) |
| PPSV23 | 2/351 (0.6%) | 25/347 (7.2%) | 237/347 (68.3%) |
| Event | V116 | PPSV23 |
|---|---|---|
| Urinary tract infectionInfections and infestations | 4/527 | 0/347 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 4/527 | 2/347 |
| Anaphylactic reactionImmune system disorders | 0/527 | 2/347 |
| Respiratory tract infection viralInfections and infestations | 1/527 | 2/347 |
| PneumoniaInfections and infestations | 3/527 | 1/347 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 3/527 | 1/347 |
| Cardiogenic shockCardiac disorders | 2/527 | 0/347 |
| Dengue feverInfections and infestations | 2/527 | 1/347 |
| Pneumonia viralInfections and infestations | 2/527 | 0/347 |
| Cardiopulmonary failureCardiac disorders | 0/527 | 1/347 |
| Event | V116 | PPSV23 |
|---|---|---|
| Injection site painGeneral disorders | 357/527 | 189/347 |
| Injection site erythemaGeneral disorders | 130/527 | 57/347 |
| FatigueGeneral disorders | 107/527 | 73/347 |
| Injection site swellingGeneral disorders | 99/527 | 63/347 |
| HeadacheNervous system disorders | 94/527 | 53/347 |
| MalaiseGeneral disorders | 70/527 | 33/347 |
| IrritabilityPsychiatric disorders | 61/527 | 38/347 |
| SomnolenceNervous system disorders | 50/527 | 32/347 |
| PyrexiaGeneral disorders | 33/527 | 25/347 |
| MyalgiaMusculoskeletal and connective tissue disorders | 34/527 | 18/347 |
| Age, Continuous(Years) | V116 | PPSV23 | Total |
|---|---|---|---|
| Mean | 8.2 ± 4.1 | 7.8 ± 3.8 | 8.0 ± 4.0 |
| Sex: Female, Male(Participants) | V116 | PPSV23 | Total |
|---|---|---|---|
| Female | 220 | 142 | 362 |
| Male | 311 | 209 | 520 |
| Ethnicity (NIH/OMB)(Participants) | V116 | PPSV23 | Total |
|---|---|---|---|
| Hispanic or Latino | 233 | 158 | 391 |
| Not Hispanic or Latino | 298 | 192 | 490 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | V116 | PPSV23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 48 | 43 | 91 |
| Asian | 48 | 37 | 85 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 31 | 20 | 51 |
| White | 322 | 203 | 525 |
| More than one race | 82 | 48 | 130 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jan 2024 to primary completion in Feb 2025, 13 months.
Results were first posted in Mar 2026, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 13 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine